Cargando…

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients

The introduction of protease inhibitors (PI) containing antiretroviral regimens in the treatment of HIV infection in infants, children, and adolescents has dramatically decreased morbidity and mortality. Darunavir, the latest PI to be FDA approved for pediatric patients older than 6 years and curren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dobroszycki, Joanna, Abadi, Jacobo, Wiznia, Andrew A, Rosenberg, Michael G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926773/ https://www.ncbi.nlm.nih.gov/pubmed/24600277 http://dx.doi.org/10.2147/AHMT.S11177

Ejemplares similares

Pregnancy in women with perinatally acquired HIV-infection: Outcomes and challenges
por: Phillips, Usha K., et al.
Publicado: (2011)

Impact of HIV-1 infection and pregnancy on maternal health: comparison between perinatally and behaviorally infected young women
por: Munjal, Iona, et al.
Publicado: (2013)

Immunodominance of HIV-1 Specific CD8+ T-Cell Responses Is Related to Disease Progression Rate in Vertically Infected Adolescents
por: Sharp, Elizabeth R., et al.
Publicado: (2011)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

Association of Differentiation State of CD4+ T Cells and Disease Progression in HIV-1 Perinatally Infected Children
por: Sharp, Elizabeth R., et al.
Publicado: (2012)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
por: Navarro, Jordi, et al.
Publicado: (2016)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley, Rustin D, et al.
Publicado: (2016)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
por: Chavda, Vivek P., et al.
Publicado: (2021)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir
por: Opsomer, Magda, et al.
Publicado: (2018)

Darunavir does not prevent SARS-CoV-2 infection in HIV patients
por: Riva, Agostino, et al.
Publicado: (2020)

Pediatric Asthma: A Global Epidemic
por: Serebrisky, Denise, et al.
Publicado: (2019)

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data
por: Daskapan, Alper, et al.
Publicado: (2019)

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily
por: Zorrilla, CD, et al.
Publicado: (2014)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Pharmacotherapy of pediatric and adolescent HIV infection
por: Schuval, Susan J
Publicado: (2009)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
por: Gisslén, Magnus, et al.
Publicado: (2012)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated with Darunavir
por: Opsomer, Magda, et al.
Publicado: (2018)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir
por: Garvey, LJ, et al.
Publicado: (2010)

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥3 to <12 Years
por: Brochot, A, et al.
Publicado: (2015)

The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms
por: Gao, Xiaobo, et al.
Publicado: (2019)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Intranasal delivery of darunavir improves brain drug concentrations in mice for effective HIV treatment
por: Kumar, Asit, et al.
Publicado: (2022)

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
por: Fenley, Juliana de C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p060ng9advqib31icdkeuac2e7